Next Phase Newsletter

A Venture Capital company based in USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has long term relationships with several Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast of the US, although they are also open to review opportunities in North America.

The firm is looking for seed and early-stage medical device and diagnostic companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €4-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Recently founded by a leading venture capital firm, this new firm is interested in investing in and establishing strategic partnerships with innovative medtech companies. The firm is looking for domestic and cross-border partnerships in terms of equity investment, license-in, distribution and others. The firm can invest anywhere from hundreds of thousands to 10MM USD, and is open to both leading and co-investing. The firm looks for opportunities globally.

The firm focuses on all classes of medical devices, including PMA, 510k and software enabled devices, all the way from in-development to commercialization stage. The firm is also interested in diagnostics/monitoring devices, PMA and 510k diagnostics technologies. The firm looks for truly innovative technologies. Interested indications include but are not limited to minimally invasive surgical devices, neurology, oncology, ophthalmic, dental, urology, GI and ENT.

The firm has no specific requirement for the company and its management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life-sciences focused venture capital firm currently making investments into US-based companies out of its fourth fund primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment.  The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact investment arm of a non-profit organization manages an evergreen fund and is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that align with the firm’s mission to advance the fight against cancer. The firm will invest in companies of all stages of development (excluding public companies), and looks for companies that are advancing science, reducing disparities, and promoting health care sustainability; though there is a preference for Seed and Series A stage companies. The firm’s typical check size ranges from $250K-$2 million per round and reserves additional funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US.

While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, The firm will only invest in companies relevant to the indication of oncology.

The firm is looking to co-invest in private companies only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm is investing from its second fund and manages about $150M AUM. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.